Humacyte presents case report on bioengineered vessel in infected vascular reconstruction

Humacyte presents case report on bioengineered vessel in infected vascular reconstruction
Humacyte unveils vessel case report

Humacyte presented a clinical case report highlighting the use of a bioengineered human acellular vessel in reconstructing an infected vascular site.

The case was delivered by Rishi Kundi, MD during Session 3: Lower Extremity Arterial – Part 1, aiming to address complex surgical scenarios where infection complicates vessel repair.

Humacyte has previously presented interim Phase 3 V012 results on its acellular tissue-engineered vessel (ATEV) for hemodialysis access in women at Kidney Week, according to company disclosures. The company also released long-term clinical data indicating that the ATEV vessel showed low susceptibility to atherosclerosis in 52 patients, as reported in earlier findings. These prior updates provide context for Humacyte’s ongoing clinical initiatives in vascular reconstruction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.